ID
42317
Beschrijving
Study ID: 108708 Clinical Study ID: 108708 Study Title: A phase IIb, controlled, randomized, multicentre, observer blinded study to evaluate the immunogenicity, safety and reactogenicity of a second vaccination with the low dose influenza vaccine adjuvanted with AS03 compared to a second dose of FluarixTM (GlaxoSmithKline Biologicals) administered intramuscularly in elderly >= 60 years previously vaccinated in FLU-LD-002 clinical trial Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00385840 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Influenza Vaccine GSK1247446A Trade Name: FluarixTM Study Indication: Influenza
Trefwoorden
Versies (1)
- 29-05-21 29-05-21 -
Houder van rechten
GlaxoSmithKline
Geüploaded op
29 mei 2021
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Immunogenicity, safety and reactogenicity of a second vaccination with the low dose influenza vaccine adjuvanted with AS03 NCT00385840
Visit 1, Day 0 Vaccination: Informed Consent; Demographics; Randomisation
Similar models
Visit 1, Day 0 Vaccination: Informed Consent; Demographics; Randomisation
C0019994 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,2])
C0019994 (UMLS CUI [1,2])
C1522541 (UMLS CUI-2)
C0600091 (UMLS CUI [1,2])